Generic
Secukinumab
1 brands available in the market
At a glance
Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively inhibits IL-17A. It is used for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis.
Description
Secukinumab is a recombinant fully human IgG1/κ monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of pro-inflammatory cytokines, chemokines, and mediators of tissue damage.
Indications
- Moderate-to-severe plaque psoriasis (candidates for systemic therapy or phototherapy)
- Moderate-to-severe scalp psoriasis
- Active psoriatic arthritis (PsA)
- Active ankylosing spondylitis (AS)
Therapeutic class
Drugs for Osteoarthritis & Rheumatoid Arthritis
Pharmacological class
IL-17A Inhibitor (Monoclonal Antibody)
Pharmacology
Secukinumab selectively binds to and inhibits IL-17A, a pro-inflammatory cytokine produced by Th17 cells, mast cells, neutrophils, and dendritic cells. IL-17A inhibition reduces inflammatory cell activation, cytokine release, and tissue damage, improving symptoms in psoriasis and inflammatory arthritis.
Mechanism of action
Selectively inhibits IL-17A to reduce inflammation and tissue damage.
Dosage
Adult Dose (Subcutaneous):
- Plaque psoriasis: 300 mg at Weeks 0,1,2,3,4; then 300 mg every 4 weeks (150 mg may be acceptable)
- Psoriatic arthritis (with coexistent plaque psoriasis): Same as above
- Psoriatic arthritis (others): 150 mg at Weeks 0,1,2,3,4; then every 4 weeks; increase to 300 mg if inadequate response
- Ankylosing spondylitis: 150 mg at Weeks 0,1,2,3,4; then every 4 weeks
Administration
- Subcutaneous injection (Sensoready pen or prefilled syringe)
- 150 mg vial: Reconstitute with 1 mL sterile water to make 150 mg/mL solution
- First dose should be taken under medical supervision
Missed dose
If you miss a dose, consult your doctor.
Side effects
Common Side Effects (>10%):
- Infections (28.7%)
- Nasopharyngitis (11.4-12.3%)
1-10%:
- Diarrhea (2.6-4.1%)
- URT infection (2.5-3.2%)
- Rhinitis (1.4%)
- Oral herpes (0.1-1.3%)
- Pharyngitis (1-1.2%)
- Urticaria (0.6-1.2%)
Precautions & warnings
- Do not use in serious infections (active TB, hepatitis B, sepsis)
- Caution in history of chronic or recurrent infections
- Caution in inflammatory bowel disease (Crohn's disease)
- Do not use with live vaccines
- Caution in pregnancy and lactation
Contraindications
- Serious infections (active TB, hepatitis B, sepsis)
- Administration of live vaccines
- Serious hypersensitivity to secukinumab or any excipient
Drug interactions
- Live vaccines: May enhance adverse effects and diminish therapeutic effect
Food interactions
Caution is advised when consuming alcohol with Secukinumab; consult your doctor.
Use in pregnancy
Use in Pregnancy: Limited human data; no adverse effects in animal studies; use only if clearly needed; consult your doctor.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Unknown if excreted in human milk; consider benefits of breastfeeding and maternal clinical need; consult your doctor.
Pediatric use
Safety and effectiveness not established in pediatric patients
Geriatric use
No overall differences observed between elderly and younger patients
Renal / hepatic impairment
Not applicable
Overdose effects
Doses up to 30 mg/kg IV were tolerated; in overdose, provide symptomatic treatment.
Storage conditions
Store at 2-8°C in a refrigerator; do not freeze; keep in original carton to protect from light; do not shake; discard any unused portion.
Chemical structure
Secukinumab